Novartis 1Q13 1Q Revenues: $14.0 billion (+2%) 1Q: Earnings: $2.4 billion (+7%) Comments: Phamaceutical revenues were flat at $7.9 billion. Sales of growth products were up 14% to $4.2 billion, offsetting generic losses of $500 million from Diovan’s patent expiration. Gilenya sales were $421 million (+71%), Afinitor was $303 million (+114%), Tasigna was $284 million (+39%), Galvus was $267 million (+40%), and Lucentis rose 7% to $596 million. Sandoz (generic) slew were up 6% to $2.3 bil...